West Paces Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

West Paces Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6K	Buy	+25	New	+$17K	﹤0.01%	360
2025 Q2	–	Sell	-27	Closed	-$17.1K	–	482
2025 Q1	$17.1K	Hold	27	–	–	﹤0.01%	307
2024 Q4	$19.2K	Hold	27	–	–	﹤0.01%	306
2024 Q3	$28.4K	Hold	27	–	–	0.01%	280
2024 Q2	$28.4K	Hold	27	–	–	0.01%	268
2024 Q1	$26K	Buy	27 +23	+575%	+$21.9K	0.01%	287
2023 Q4	$3.51K	Buy	4 +2	+100%	+$1.65K	﹤0.01%	432
2023 Q3	$1.65K	Hold	2	–	–	﹤0.01%	436
2023 Q2	$1.44K	Sell	2 -1	-33%	-$771	﹤0.01%	468
2023 Q1	$2.46K	Buy	3 +1	+50%	+$754	﹤0.01%	457
2022 Q4	$1.44K	Hold	2	–	–	﹤0.01%	455
2022 Q3	$1.38K	Buy	+2	New	+$1.26K	﹤0.01%	452
2022 Q2	–	Sell	-2	Closed	-$1.4K	–	599
2022 Q1	$1.4K	Buy	+2	New	+$1.26K	﹤0.01%	507
2021 Q2	–	Sell	-40	Closed	-$18.9K	–	625
2021 Q1	$18.9K	Buy	+40	New	+$19.5K	0.01%	271
2017 Q1	–	Sell	-22	Closed	-$8.08K	–	537
2016 Q4	$8.08K	Buy	+22	New	+$8.37K	0.01%	360

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

West Paces Advisors's REGN Position: Q2 2026 in Review

West Paces Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 25 shares worth $15.6K. The stake represents ﹤0.01% of the portfolio and ranks #360 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in REGN as recently as Q1 2025.

West Paces Advisors first reported a position in REGN in Q4 2016 and has held it in 15 quarters since. The position peaked at $28.4K in Q3 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

West Paces Advisors held 25 shares of Regeneron Pharmaceuticals worth $15.6K as of Q2 2026.
Regeneron Pharmaceuticals was a new West Paces Advisors position in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #360 holding.
West Paces Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 15 quarters since.
West Paces Advisors's Regeneron Pharmaceuticals position peaked at $28.4K in Q3 2024.
1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.